Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 192

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 192
---
   2,901,341 |   |     |                   |  (7,500,000 | ) |
| Payment of loan premium                                                                                      |     |                   |    (850,000 | ) |     |                   |           - |   |
| Payments of note payable                                                                                     |     |                   |  (5,000,000 | ) |     |                   |           - |   |
| Net cash provided by financing activities                                                                    |     |                   |  12,725,954 |   |     |                   |  20,302,939 |   |
| Net change in cash and cash equivalents                                                                      |     |                   |    (691,784 | ) |     |                   |  10,889,454 |   |
| Cash and cash equivalents, beginning of period                                                               |     | $                 |  23,843,798 |   |     | $                 |  19,460,883 |   |
| Cash and cash equivalents, end of period                                                                     |     | $                 |  23,152,014 |   |     | $                 |  30,350,337 |   |
| SUPPLEMENTAL CASH FLOW INFORMATION:                                                                          |     |                   |             |   |     |                   |             |   |
| Cash paid for interest                                                                                       |     | $                 |     178,932 |   |     | $                 |   1,293,419 |   |
| SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:                                                     |     |                   |             |   |     |                   |             |   |
| Right of use assets obtained in exchange for lease obligations                                               |     | $                 |           - |   |     | $                 |     432,192 |   |
| Reclassification of unrealized gains on U.S. Treasury Bills (available-for-sale investments) upon settlement |     | $                 |           - |   |     | $                 |     176,591 |   |
| Deemed dividend for ratchet adjustment to warrants                                                           |     | $                 |     369,465 |   |     | $                 |     886,423 |   |

<div align='center'>See accompanying notes to unaudited condensed financial
statements

F-29

BioVie Inc.

Notes to Condensed Financial Statements

For the Three and Nine Months Ended March 31, 2025 and 2024